CIBC Asset Management Inc increased its position in Equifax Inc. (NYSE:EFX – Get Rating) by 9.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,386 shares of the credit services provider’s stock after buying an additional 1,429 shares during the period. CIBC Asset Management Inc’s holdings in Equifax were worth $2,809,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. United Capital Financial Advisers LLC grew its stake in shares of Equifax by 4.0% in the 1st quarter. United Capital Financial Advisers LLC now owns 1,411 shares of the credit services provider’s stock valued at $334,000 after buying an additional 54 shares during the period. MAI Capital Management grew its stake in shares of Equifax by 3.9% in the 2nd quarter. MAI Capital Management now owns 1,473 shares of the credit services provider’s stock valued at $269,000 after buying an additional 55 shares during the period. First Horizon Advisors Inc. grew its stake in shares of Equifax by 32.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 243 shares of the credit services provider’s stock valued at $44,000 after buying an additional 59 shares during the period. Rovin Capital UT ADV lifted its position in Equifax by 2.5% in the 3rd quarter. Rovin Capital UT ADV now owns 2,571 shares of the credit services provider’s stock valued at $441,000 after acquiring an additional 62 shares in the last quarter. Finally, Clarius Group LLC lifted its position in Equifax by 6.2% in the 2nd quarter. Clarius Group LLC now owns 1,119 shares of the credit services provider’s stock valued at $205,000 after acquiring an additional 65 shares in the last quarter. 93.84% of the stock is currently owned by institutional investors and hedge funds.
Equifax Trading Down 0.1 %
Shares of EFX stock opened at $221.98 on Wednesday. The company has a 50 day moving average of $201.53 and a 200-day moving average of $192.12. The company has a quick ratio of 0.64, a current ratio of 0.64 and a debt-to-equity ratio of 1.28. Equifax Inc. has a 12-month low of $145.98 and a 12-month high of $245.27. The firm has a market cap of $27.18 billion, a P/E ratio of 38.54 and a beta of 1.42.
Equifax Dividend Announcement
Analyst Ratings Changes
EFX has been the topic of several recent research reports. StockNews.com cut shares of Equifax from a “hold” rating to a “sell” rating in a research report on Wednesday, January 11th. Stifel Nicolaus raised their price target on shares of Equifax from $181.00 to $222.00 in a research report on Friday, December 9th. The Goldman Sachs Group raised their price target on shares of Equifax from $187.00 to $212.00 and gave the company a “neutral” rating in a research report on Tuesday, January 10th. Atlantic Securities raised shares of Equifax from a “neutral” rating to an “overweight” rating and set a $230.00 target price on the stock in a research report on Tuesday, November 15th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Equifax from $160.00 to $175.00 in a research report on Tuesday, December 20th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $206.13.
Equifax, Inc engages in the provision of information solutions and human resources business process outsourcing services. It operates through the following business segments: U.S. Information Solutions, Workforce Solutions and International. The U.S. Information Solutions segment includes consumer and commercial information services, mortgage loan origination information, financial marketing services, and identity management.
- Get a free copy of the StockNews.com research report on Equifax (EFX)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Equifax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equifax and related companies with MarketBeat.com's FREE daily email newsletter.